{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:38:16Z","timestamp":1780583896113,"version":"3.54.1"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>We aimed to explore the pathways followed by patients with overactive bladder (OAB) from referral to the urologist to final treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a single\u2010center, retrospective cohort study of female patients diagnosed with OAB in a large Dutch nonacademic teaching hospital. The number, sequence, and duration of treatment steps offered were analyzed, and the effectiveness, reasons for discontinuation, and possible case\u2010mix variables influencing OAB treatment were studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 120 patients were enrolled and required a median of 2 steps (range, 1\u20136) of treatment over a median total duration of 28 weeks (range, 5\u2013256). Treatment typically started with drug therapy, including antimuscarinics (38%; 95% CI, 30%\u201347%), antimuscarinics plus pelvic floor muscle therapy (21%; 95% CI, 15%\u201329%), or mirabegron (11%; 95% CI, 6%\u201318%). However, 52% of patients required further treatment, with botulinum toxin A (BoNT\u2010A) injections being most effective (67%; 95% CI, 42%\u201385%), followed by antimuscarinics plus percutaneous tibial nerve stimulation (50%; 95% CI, 25%\u201375%), and antimuscarinics plus pelvic floor muscle therapy (36%; 95% CI, 21%\u201354%). Other therapies showed lower effectiveness. Common reasons for discontinuation were insufficient response and side effects. Overall, 22 patients were lost to follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Most patients try at least two treatments before they experience satisfactory symptom relief, with treatment evaluations requiring time because therapeutic onsets differ by patient and treatment. Our data can help to manage expectations among urologists and patients when seeking treatment for OAB.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.24817","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T21:42:23Z","timestamp":1634247743000},"page":"290-295","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The patient pathway for overactive bladder management: A quantitative analysis"],"prefix":"10.1002","volume":"41","author":[{"given":"Auke. J.","family":"Seinen","sequence":"first","affiliation":[{"name":"Department of Urology Isala Clinics Zwolle The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier","family":"Elburg","sequence":"additional","affiliation":[{"name":"Department of Urology Isala Clinics Zwolle The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne M.","family":"Hollegien","sequence":"additional","affiliation":[{"name":"Department of Urology Isala Clinics Zwolle The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco H.","family":"Blanker","sequence":"additional","affiliation":[{"name":"Department of General Practice and Elderly Care Medicine UMCG Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1567-4847","authenticated-orcid":false,"given":"Lambertus P. W.","family":"Witte","sequence":"additional","affiliation":[{"name":"Department of Urology Isala Clinics Zwolle The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.038"},{"key":"e_1_2_11_3_1","article-title":"NHG\u2010standaard \u2018Incontinentie voor urine bij vrouwen\u2019 [Practice guideline \u2018Urinary incontinence in women\u2019 from the Dutch College of General Practitioners]","volume":"160","author":"Damen\u2010van Beek Z","year":"2016","journal-title":"Ned Tijdschr Geneeskd"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.12.031"},{"key":"e_1_2_11_5_1","article-title":"Richtlijn urine\u2010incontinentie voor de tweede\u2010 en derdelijnszorg versie 2.0","author":"Bosch R","year":"2014","journal-title":"Ned Ver Voor Obstet Gynaecol"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.09.079"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.047"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22505"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.01.037"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02626.x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09036.x"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01098-y"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-002-0301-4"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021889"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.24254"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-016-1862-y"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10729-006-9096-y"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-017-3481-6"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.08.030"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22544"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14189"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.24817","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/nau.24817","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.24817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:28:32Z","timestamp":1692952112000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.24817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1002\/nau.24817"],"URL":"https:\/\/doi.org\/10.1002\/nau.24817","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"assertion":[{"value":"2021-06-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}